School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Immuneering Corp IMRX

Healthcare · Biotechnology

$3.94last close 2026-10-09 · market cap $249.73M · delayed data

Trailing returns

1M-9.60%
3M-24.46%
6M-30.07%
1Y-37.03%
5Y-82.23%

Basis: Adjusted daily closes.

What it does

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.

Open IMRX in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies